Patients More Adherent To Mobile, Web-based Sleep Apnea Therapy
Obstructive sleep apnea patients using the SleepMapper mobile app and web-based platform achieved a 22 percent higher positive airway pressure (PAP) therapy adherence rate than non-users, according to a study by Philips Respironics.
Obstructive sleep apnea patients using the SleepMapper mobile app and web-based platform achieved a 22 percent higher positive airway pressure (PAP) therapy adherence rate than non-users, according to a study by Philips Respironics.
Results of the study were presented at the SLEEP 2014 conference.
To test the effectiveness of SleepMapper, researchers randomly analyzed over 15,000 patients from the Philips Respironics EncoreAnywhere database and compared adherence and usage rates between those who were provided with SleepMapper upon initial PAP setup and those who were not. Patients who were provided with SleepMapper achieved a 78 percent adherence rate based upon the Centers for Medicare and Medicaid (CMS) guidelines, compared to the average 56 percent compliance rate among patients who were not provided with SleepMapper.
In addition, patients who were provided with SleepMapper slept an average of 1.4 hours longer on PAP than patients who were not provided with SleepMapper. As for new PAP patients struggling to manage and accept their therapy, 33 percent of those who engaged with SleepMapper were able to meet adherence guidelines within 90 days, compared to just 11 percent who were not provided with the tool.
SleepMapper is an interactive mobile and web-based application that enables patients to take a more active role in their PAP therapy and better utilize their PAP device for more effective treatment. SleepMapper engages patients by providing them with feedback on their individual adherence and therapy information, while also using empirically-tested behavior change therapies to motivate patients and keep them interested. It works with Philips Respironics' patient management system and most of its System One devices.
Results of the study were presented at the SLEEP 2014 conference.
To test the effectiveness of SleepMapper, researchers randomly analyzed over 15,000 patients from the Philips Respironics EncoreAnywhere database and compared adherence and usage rates between those who were provided with SleepMapper upon initial PAP setup and those who were not. Patients who were provided with SleepMapper achieved a 78 percent adherence rate based upon the Centers for Medicare and Medicaid (CMS) guidelines, compared to the average 56 percent compliance rate among patients who were not provided with SleepMapper.
In addition, patients who were provided with SleepMapper slept an average of 1.4 hours longer on PAP than patients who were not provided with SleepMapper. As for new PAP patients struggling to manage and accept their therapy, 33 percent of those who engaged with SleepMapper were able to meet adherence guidelines within 90 days, compared to just 11 percent who were not provided with the tool.
SleepMapper is an interactive mobile and web-based application that enables patients to take a more active role in their PAP therapy and better utilize their PAP device for more effective treatment. SleepMapper engages patients by providing them with feedback on their individual adherence and therapy information, while also using empirically-tested behavior change therapies to motivate patients and keep them interested. It works with Philips Respironics' patient management system and most of its System One devices.
More for you
Loading data for hdm_tax_topic #better-outcomes...